The course is designed to provide students with the skills to understand the molecular basis of cancer development and progression. It covers the development of various therapeutic treatment options and guides students to an assessment of the optimal treatment options available for various cancers. Students will explore the way cancer medicines are assessed for safety and efficacy and how patients are monitored for response to therapy. Recent advances in pharmacology, pharmacogenetics, molecular biology and data analysis have converged to revolutionise the treatment of cancer, extending patient lifespans and turning some cancers into chronic conditions. Targeted therapies are rapidly improving patient outcomes while reducing un-necessary exposure in patients unlikely to respond to a particular therapy. The future now is how to combine therapies and rationally choose the best treatment options for an individual patient at different stages of their disease. Finally we look into the ethics and economics of cancer therapy and how and who should bear the burden of cost for these new advances in clinical medicine.
Please note that the University reserves the right to vary student fees in line with relevant legislation. This fee information is provided as a guide and more specific information about fees, including fee policy, can be found on the fee website.
For advice about fees for courses with a fee displayed as "Not Applicable", including some Work Experience and UNSW Canberra at ADFA courses, please contact the relevant Faculty.
Where a Commonwealth Supported Students fee is displayed, it does not guarantee such places are available.